Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Endocrine 3Sarcoma 1Gynecologic 1Breast 1

Conditions

Sarcoma 78Osteosarcoma 34Melanoma 22Sarcoma, Ewing 20Neuroblastoma 19Rhabdomyosarcoma 17Ovarian Neoplasms 17Gastrointestinal Stromal Tumors 17Colorectal Neoplasms 16Glioblastoma 15Bone Neoplasms 15Sarcoma, Kaposi 14Rhabdoid Tumor 14Neoplasms 14Breast Neoplasms 14Wilms Tumor 13Liposarcoma 13Neoplasm Metastasis 12Gliosarcoma 12Medulloblastoma 11Lymphoma, Non-Hodgkin 11Hepatoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Stomach Neoplasms 10Neurofibrosarcoma 10Thyroid Neoplasms 9Recurrence 9Pancreatic Neoplasms 9Ependymoma 9

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × Sarcoma × 30 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡